Department of Pathology, University Hospitals Leuven, Herenstraat 49, 3000, Leuven, Belgium,
Virchows Arch. 2014 Mar;464(3):379-91. doi: 10.1007/s00428-013-1532-z. Epub 2014 Feb 1.
Colorectal cancer remains a major cause of cancer-related death worldwide. One way to reduce its staggering mortality rate and socio-economic burden is to predict outcome based on the aggressiveness of the tumor biology in order to treat patients accordingly to their risk profile. As such, it comes as no surprise that prognostic biomarker discovery is a hot topic in colorectal cancer research. The last two decades have literally produced tons of new data and an avalanche of potential clinically applicable biomarkers. This review explores and summarizes data concerning the prognostic strength and clinical utility of current and future tissue biomarkers in the diagnosis and treatment of colorectal cancer.
结直肠癌仍然是全球癌症相关死亡的主要原因。降低其惊人死亡率和社会经济负担的一种方法是根据肿瘤生物学的侵袭性来预测预后，以便根据患者的风险状况进行治疗。因此，在结直肠癌研究中发现预后生物标志物是一个热门话题也就不足为奇了。在过去的二十年中，实际上已经产生了大量的新数据和大量潜在的临床应用生物标志物。本综述探讨并总结了当前和未来组织生物标志物在结直肠癌诊断和治疗中的预后强度和临床应用的相关数据。
